deltatrials
Suspended PHASE3 NCT02037529

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Sponsor: Academic and Community Cancer Research United

Conditions Breast Adenocarcinoma HER2/Neu Negative Invasive Breast Carcinoma Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7
Interventions Eribulin Mesylate Laboratory Biomarker Analysis Paclitaxel Quality-of-Life Assessment
Updated 27 times since 2017 Last updated: Jul 24, 2024 Started: Jan 17, 2014 Primary completion: Feb 11, 2021 Completion: Oct 31, 2024

A PHASE3 clinical study on Breast Adenocarcinoma and HER2/Neu Negative, this trial is suspended. The trial is conducted by Academic and Community Cancer Research United and has accumulated 27 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

27 versions recorded

  1. Sep 2025 — Present [monthly]

    Suspended PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Suspended PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Suspended PHASE3

  5. Jun 2022 — Oct 2023 [monthly]

    Suspended PHASE3

▶ Show 22 earlier versions

  1. May 2022 — Jun 2022 [monthly]

    Suspended PHASE3

  2. Apr 2022 — May 2022 [monthly]

    Suspended PHASE3

  3. Mar 2022 — Apr 2022 [monthly]

    Suspended PHASE3

  4. Oct 2021 — Mar 2022 [monthly]

    Suspended PHASE3

  5. Sep 2021 — Oct 2021 [monthly]

    Suspended PHASE3

  6. Jun 2021 — Sep 2021 [monthly]

    Suspended PHASE3

  7. May 2021 — Jun 2021 [monthly]

    Suspended PHASE3

  8. Jan 2021 — May 2021 [monthly]

    Suspended PHASE3

  9. Oct 2020 — Jan 2021 [monthly]

    Suspended PHASE3

  10. Aug 2020 — Oct 2020 [monthly]

    Suspended PHASE3

  11. Mar 2020 — Aug 2020 [monthly]

    Suspended PHASE3

  12. Feb 2020 — Mar 2020 [monthly]

    Suspended PHASE3

  13. Dec 2019 — Feb 2020 [monthly]

    Suspended PHASE3

  14. Sep 2019 — Dec 2019 [monthly]

    Suspended PHASE3

  15. Aug 2019 — Sep 2019 [monthly]

    Suspended PHASE3

  16. Mar 2019 — Aug 2019 [monthly]

    Suspended PHASE3

    Status: Active Not Recruiting → Suspended

  17. Jul 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  18. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  19. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  20. Aug 2017 — Mar 2018 [monthly]

    Recruiting PHASE3

  21. Feb 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  22. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academic and Community Cancer Research United
  • National Cancer Institute (NCI)
Data source: Academic and Community Cancer Research United

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Asheville, United States, Brewer, United States, Burlington, United States, Cedar Rapids, United States, Chapel Hill, United States, Chicago, United States, Columbia, United States, Des Moines, United States, Duluth, United States, East Syracuse, United States and 26 more location s